Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's presentation is scheduled for Tuesday, August 12, 2025, at 10:30 A.M. EDT.
Investors can access the live webcast through the provided link or via Madrigal's Investor Relations Events and Presentations page. A replay will be made available following the event.
Madrigal Pharmaceuticals (NASDAQ: MDGL) ha annunciato la propria partecipazione al Canaccord Genuity 45th Annual Growth Conference. La presentazione è programmata per martedì 12 agosto 2025 alle 10:30 A.M. EDT.
Gli investitori potranno seguire la diretta web tramite il link fornito o dalla pagina Investor Relations "Events and Presentations" di Madrigal. Una replica sarà disponibile dopo l'evento.
Madrigal Pharmaceuticals (NASDAQ: MDGL) anunció su participación en la Canaccord Genuity 45th Annual Growth Conference. La presentación está programada para el martes 12 de agosto de 2025 a las 10:30 A.M. EDT.
Los inversores podrán acceder a la transmisión en vivo mediante el enlace proporcionado o a través de la página de Investor Relations —Events and Presentations— de Madrigal. La repetición estará disponible tras el evento.
Madrigal Pharmaceuticals (NASDAQ: MDGL)는 Canaccord Genuity 45th Annual Growth Conference에 참가한다고 발표했습니다. 회사의 발표는 2025년 8월 12일 화요일 오전 10시 30분(EDT)에 예정되어 있습니다.
투자자들은 제공된 링크 또는 Madrigal의 Investor Relations 'Events and Presentations' 페이지를 통해 생중계에 접속할 수 있습니다. 행사 종료 후 재방송이 제공됩니다.
Madrigal Pharmaceuticals (NASDAQ: MDGL) a annoncé sa participation à la Canaccord Genuity 45th Annual Growth Conference. La présentation de la société est prévue pour le mardi 12 août 2025 à 10h30 A.M. EDT.
Les investisseurs peuvent accéder à la retransmission en direct via le lien fourni ou depuis la page Investor Relations — Events and Presentations — de Madrigal. Un replay sera mis en ligne après l'événement.
Madrigal Pharmaceuticals (NASDAQ: MDGL) gab bekannt, dass das Unternehmen an der Canaccord Genuity 45th Annual Growth Conference teilnehmen wird. Die Präsentation ist für Dienstag, den 12. August 2025, um 10:30 A.M. EDT angesetzt.
Investoren können das Live-Webcast über den bereitgestellten Link oder über Madrigals Investor-Relations-Seite "Events and Presentations" verfolgen. Eine Aufzeichnung wird nach der Veranstaltung verfügbar sein.
- None.
- None.
CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event.
About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
When is Madrigal Pharmaceuticals (MDGL) presenting at the Canaccord Genuity Conference 2025?
How can investors watch Madrigal Pharmaceuticals' (MDGL) Canaccord conference presentation?
What is the name of the conference where Madrigal Pharmaceuticals (MDGL) will present?
Will there be a replay available of Madrigal Pharmaceuticals' (MDGL) conference presentation?
